Results 71 to 80 of about 6,337 (198)

Symptoms Associated With Detection of Viral Versus Bacterial Pathogens in Outpatients With Lower Respiratory Infections

Influenza and Other Respiratory Viruses, Volume 20, Issue 3, March 2026.
ABSTRACT Purpose This study aims to identify symptoms that predict a high likelihood of viral infection, so these patients could be triaged for home care to avoid antibiotics. Methods We recruited adults presenting to US primary or urgent care sites with a chief complaint of cough and symptoms consistent with LRTI. Data collected included demographics,
Mark Ebell, Dan J. Merenstein, Bruce Barrett, Cassie Hulme, Sarah Walters, Caroline Hamer, Michelle Buhr   +6 more
wiley   +1 more source

The association between COVID‐19 and incident gestational diabetes (GDM): A population‐based case–control study of the National Health Insurance Research Database in Taiwan

Journal of Diabetes Investigation, Volume 17, Issue 3, Page 527-534, March 2026.
Our study found no evidence that COVID‐19 infection is linked to gestational diabetes; however, it shows some evidence of an association between vaccination and a reduced risk. ABSTRACT Background Reports suggested that diabetes could be a complication arising from COVID‐19; however, the relationship between COVID‐19 and the development of gestational ...
Liang‐Yu Lin, Chi‐Jen Chen, Mei‐Huei Chen, Chun‐Wei Chen, Pau‐Chung Chen   +4 more
wiley   +1 more source

Machine Learning‐Guided Repositioning of a SARS‐CoV‐2‐Targeting Molecular Series as Cruzain Inhibitors

ChemMedChem, Volume 21, Issue 2, January 2026.
An ExtraTrees machine learning (ML) model is used to reposition a SARS‐CoV‐2‐directed library of peptidomimetic compounds as cruzain inhibitors for Chagas disease. Potent binders with a novel P1 moiety (for cruzain) are identified and validated by calorimetry.
Rafael F. Lameiro, Luiz F. Barbosa, Evelin R. Cardoso, Beatriz Siqueira Ho, Felipe Cardoso Prado Martins, Bruna C. de Melo, Fabiana Rosini, Anwar Shamim, Priscila M. Souza, Wellington Falcão de Souza, Carlos A. Montanari   +10 more
wiley   +1 more source

Insights from a community-based survey on factors influencing acceptance and uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 antiviral medication in Singapore

BMC Public Health
Introduction Antiviral treatment can reduce the burden of COVID-19. But utilisation can be suboptimal, even in a setting like Singapore where it is fully subsidized for those with selected medical conditions and older adults (≥ 50 years).
Sheng En Alexius Matthias Soh, Wei Ling Brenda Ong, Tun-Linn Thein, Konstadina Griva, I.-Cheng Mark Chen   +4 more
doaj   +1 more source

Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID‐19 Encounter: A Retrospective Cohort Study From Alberta, Canada

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 1, January 2026.
ABSTRACT Purpose To describe the characteristics of adults who had a severe coronavirus disease 2019 (COVID‐19) outcome during a timeframe that nirmatrelvir/ritonavir (NMV‐r; Paxlovid) was available, to assess medical eligibility and receipt of NMV‐r before presentation to acute care.
Sylvia Aponte‐Hao, Khanh Vu, Jason R. Randall, Karen J. B. Martins, Phuong Uyen Nguyen, Lynora Saxinger, Jenine Leal, Elissa Rennert‐May, Ellen Rafferty, Tyler Williamson, Scott W. Klarenbach   +10 more
wiley   +1 more source

The Tetrahydroisoquinoline Derivative SP9 Exhibits Antiviral Activity Against PEDV and MHV

Transboundary and Emerging Diseases, Volume 2026, Issue 1, 2026.
Coronaviruses exhibit high mutation rates and cross‐species transmissibility, posing a persistent threat to human and animal health and underscoring the urgent need for antivirals that can compensate for the limited crossprotection afforded by current vaccines.
Junhai Zhu, Yuting Jiang, Kaifang Yang, Fei Gao, Wenbao Qi, Lihong Huang, Yue Wang, Bin Li   +7 more
wiley   +1 more source

Support Vector Machine Identification of Small Molecule Binders to an Understudied Allosteric Site of SARS‐CoV‐2 Mpro for Next‐Generation PROTAC‐Based Therapeutics

Archiv der Pharmazie, Volume 358, Issue 12, December 2025.
An SVM‐based ML model identified 180 potential SARS‐CoV‐2 Mpro inhibitors. MST experiments confirmed three high‐affinity binders, with one showing Kd = 2.8 ± 0.9 μM. These compounds are non‐competitive, suggesting binding to a novel allosteric site.
Enrico Mario Alessandro Fassi, Nedra Mekni, Marco Albani, Sabine Maehrlein, Annabelle Carolin Weldert, Tanja Schirmeister, Thierry Langer, Giovannf razioso   +7 more
wiley   +1 more source

Exploring Nirmatrelvir Derivatives Through P2 Substituent Modifications and Warhead Innovations Targeting the Main Protease of SARS‐CoV‐2

Archiv der Pharmazie, Volume 358, Issue 11, November 2025.
This study explores structural tuning of SARS‐CoV‐2 Mpro inhibitors through P2 position substitutions and novel warheads. Combining computational modeling and biochemical assays, we found that hydrophobic π‐rich groups and uncommon warheads like fluoro‐vinylsulfone or nitrile enhance potency.
Felipe Cardoso Prado Martins, Johannes Lang, Fernanda dos Reis Rocho, Xianxian Wang, Vinícius Bonatto, Jerônimo Lameira, Christian Klein, Carlos Alberto Montanari   +7 more
wiley   +1 more source

Comparative evaluation of authorized drugs for treating Covid‐19 patients

Health Science Reports, 2022
Background and Aims Vaccines are the first line of defense against coronavirus disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid‐19 pandemic.
Towhidul Islam, Moynul Hasan, Mohammad Saydur Rahman, Md. Rabiul Islam   +3 more
doaj   +1 more source

Advancing Early Clinical Trials: The Transformative Potential of Decentralized Designs and Digital Technologies in Phase 1 Clinical Trial

Clinical Pharmacology &Therapeutics, Volume 118, Issue 5, Page 1143-1151, November 2025.
A Phase 1, open‐label, single‐dose, fixed‐sequence crossover study utilizing a hybrid decentralized clinical trial (DCT) design with and without practice sessions for wearable devices and PK sampling was conducted in eight healthy participants. Using etrasimod, the study assessed the feasibility of conducting a Phase 1 hybrid DCT by the Pfizer Clinical
Bimal K. Malhotra, Josué Kunjom Mfopou, Isabelle Huyghe, Pascal Ryckmans, Nathalie Severs, Anna Plotka, Kim‐Claire Tabner, Malgorzata Anna Jennes, Anand Bhuvanendran Nair, Anna Colzi   +9 more
wiley   +1 more source